Pharmaceutical News

RSS

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.

10 Jun 2012

New synthetic vaccine effective in killing HPV-derived cancer

Researchers at Moffitt Cancer Center have developed and tested in mice a synthetic vaccine and found it effective in killing human papillomavirus-derived cancer, a virus linked to cervical cancers among others.

10 Jun 2012

Mylan, Teva resolve generic Provigil litigation

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has resolved all disputes with Teva Pharmaceuticals USA, Inc. stemming from litigation brought by Mylan in federal court in the District of Columbia against the U.S. Food and Drug Administration (FDA) concerning Mylan's abbreviated new drug application (ANDA) for Modafinil Tablets, 100 mg and 200 mg.

8 Jun 2012

Decision Resources forecasts the launch of four new agents to treat DMD by 2021

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that interviewed experts unanimously identify a disease-modifying therapy as the highest unmet need in the treatment of Duchenne muscular dystrophy (DMD).

8 Jun 2012

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin's lymphoma.

8 Jun 2012

Modulation Therapeutics receives MMRF grant for new multiple myeloma treatment

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $500,000 through its Biotech Investment Award (BIA) program to Modulation Therapeutics. Since the inception of this MMRF program in 2006, $11.5 million has been committed to 12 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

8 Jun 2012

Anti-TNFs increase risk of shingles in patients with inflammatory rheumatic diseases

Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.

8 Jun 2012

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

GlaxoSmithKline plc (GSK) and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults.

7 Jun 2012

WHO warns of drug-resistant strains of gonorrhea

"Drug-resistant strains of gonorrhea have spread to countries across the world, the U.N. health agency said on Wednesday, and millions of patients may run out of treatment options unless doctors catch and treat cases earlier," Reuters reports.

7 Jun 2012

Young adults, adolescents with mental health disorders more likely to become long-term opioid users

Long-term use and abuse of opioid painkillers, such as OxyContin and Vicodin, has markedly increased in the United States in the last two decades. Of note, prescription opioids constitute 86.9 percent of prescription drug misuse among high school students. And last week in a two-day U.S. Food and Drug Administration public meeting, officials questioned the use of long-term opioids for chronic pain due to a lack of evidence for the effectiveness and concerns about the potential risk for addiction.

7 Jun 2012

WHO calls for greater vigilance on correct use of antibiotics against gonorrhoea

Millions of people with gonorrhoea may be at risk of running out of treatment options unless urgent action is taken, according to WHO. Already several countries, including Australia, France, Japan, Norway, Sweden and the United Kingdom are reporting cases of resistance to cephalosporin antibiotics - the last treatment option against gonorrhoea. Every year an estimated 106 million people are infected with gonorrhea, which is transmitted sexually.

7 Jun 2012

New nanomedicine cancer treatments promise to reduce severity of side effects

A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the current edition of Chemical & Engineering News.

7 Jun 2012

Cellana launches ReNew line of products at GOED conference

Cellana, Inc. announced the launch of its ReNew brand and ReNew Omega-3 line of algae-based products at the GOED (Global Organization for EPA and DHA) conference being held this week in Boston, Massachusetts.

7 Jun 2012

DODAC to discuss ThromboGenics’ new BLA for ocriplasmin intravitreal injection

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that the US Food and Drug Administration (FDA) has notified the Company that its new biologic license application (BLA) for ocriplasmin intravitreal injection will be discussed at the Dermatologic and Ophthalmic Drugs Advisory Committee scheduled for July 26, 2012.

7 Jun 2012

CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing

The HIV drugs known as CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing, researchers from the Kimmel Cancer Center at Jefferson suggest in a preclinical study published in a recent issue of Cancer Research.

7 Jun 2012

Vitamin D deficiency may be an important risk factor for erectile dysfunction

A paper just published hypothesizes that vitamin D deficiency may be an important risk factor for erectile dysfunction (ED).

7 Jun 2012

Boehringer Ingelheim updates U.S. prescribing information for Pradaxa with FDA

Boehringer Ingelheim has today announced that it has updated the US prescribing information for Pradaxa (dabigatran etexilate) in alignment with the US Food and Drug Administration (FDA) to affirm that "Pradaxa 150mg twice daily was superior in reducing ischemic and hemorrhagic strokes relative to warfarin."

7 Jun 2012

Arrowhead initiates final IND-enabling steps for ARC-520 to treat HBV

Arrowhead Research Corporation, a targeted therapeutics company, today announced that its hepatitis B virus (HBV) program has completed all internal preclinical requirements and has named a clinical candidate.

7 Jun 2012

Follow-up study finds seizure freedom in 68% of patients with JME

A 25-year follow-up study reveals that 68% of patients with juvenile myoclonic epilepsy (JME) became seizure-free, with nearly 30% no longer needing antiepileptic drug (AED) treatment. Findings published today in Epilepsia, a journal of the International League Against Epilepsy (ILAE), report that the occurrence of generalized tonic-clonic seizures preceded by bilateral myoclonic seizures, and AED polytherapy significantly predicted poor long-term seizure outcome.

6 Jun 2012

Study determines transgenerational effects of cannabinoid exposure in adolescent female rats

Mothers who use marijuana as teens-long before having children-may put their future children at a higher risk of drug abuse, new research suggests.

6 Jun 2012

Pharmaceutical News

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

New synthetic vaccine effective in killing HPV-derived cancer

Mylan, Teva resolve generic Provigil litigation

Decision Resources forecasts the launch of four new agents to treat DMD by 2021

Fluorinov Pharma receives OICR grant to develop new drug against blood cancers

Modulation Therapeutics receives MMRF grant for new multiple myeloma treatment

Anti-TNFs increase risk of shingles in patients with inflammatory rheumatic diseases

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

WHO warns of drug-resistant strains of gonorrhea

Young adults, adolescents with mental health disorders more likely to become long-term opioid users

WHO calls for greater vigilance on correct use of antibiotics against gonorrhoea

New nanomedicine cancer treatments promise to reduce severity of side effects

Cellana launches ReNew line of products at GOED conference

DODAC to discuss ThromboGenics’ new BLA for ocriplasmin intravitreal injection

CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing

Vitamin D deficiency may be an important risk factor for erectile dysfunction

Boehringer Ingelheim updates U.S. prescribing information for Pradaxa with FDA

Arrowhead initiates final IND-enabling steps for ARC-520 to treat HBV

Follow-up study finds seizure freedom in 68% of patients with JME

Study determines transgenerational effects of cannabinoid exposure in adolescent female rats

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News